Skip to main content

Advertisement

SpringerLink
Log in

Effect of Flt3 ligand gene transfer in experimental pancreatic cancer

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

Fms-like tyrosine kinase 3 receptor (Flt3) is an important receptor expressed on the cell membrane of immature antigen-presenting cells. The binding of Flt3 to its ligand (FL) activates the proliferation of dendritic cells (DCs). This mechanism is currently being evaluated in the therapy of malignant tumors. The aim of the present study was to study the effect of FL gene transfer on the immune response and tumor growth in experimental pancreatic cancer.

Materials and methods

The rat FL was sequenced and cloned from total mRNA extract of the spleen. Transfection efficiency of subcutaneously growing rat duct-like pancreatic cancer (DSL6A) with DOTAP-/cholesterol-based liposomes was tested using a pcDNA3.1-lacZ construct. Flt3 ligand production of in vitro transfected tumor cells and in vivo transfected tumors was measured by enzyme-linked immunosorbent assay. Tumor induction was achieved in Lewis rats by a subcutaneous inoculation of syngeneic pancreatic tumor cells (DSL6A). The animals were allocated into three groups: control, mock treatment, and treatment with FL plasmid. The plasmid was injected intratumorally three times per week for 2 weeks. The total observation time was 6 weeks.

Results

The tumor volume was significantly lower in the FL-transfected group during the first 3 weeks. The number of responders was significantly higher in the FL group compared with control and mock treatment. The number of CD80+ DCs in the spleen was significantly higher after FL gene transfer. The responders showed a significantly higher number of splenic natural killer (NK) cells. There were no differences of infiltrating lymphocytes, proliferation, and tumor blood vessels between the groups.

Conclusion

Intratumoral gene transfer of FL in rats activated proliferation of DCs and NK cells, which causes a moderate reduction of tumor growth. This improvement of local tumor control during the first weeks could be explained by an improved antigen presentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59:99–111

    PubMed  CAS  Google Scholar 

  2. Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma. Ann Surg 237:74–85

    Article  PubMed  Google Scholar 

  3. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez Cruz L, Lacaine F, Buell MG, Dean DC, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768

    Article  PubMed  CAS  Google Scholar 

  4. MacKenzie MJ (2004) Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5:541–549

    Article  PubMed  CAS  Google Scholar 

  5. Picozzi VJ, Traverso LW (2004) The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am 13:663–674

    Article  PubMed  Google Scholar 

  6. Nukui Y, Picozzi VJ, Traverso LW (2000) Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 179:367–371

    Article  PubMed  CAS  Google Scholar 

  7. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667

    Article  PubMed  CAS  Google Scholar 

  8. Pecher G, Haring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669–673

    Article  PubMed  CAS  Google Scholar 

  9. Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK (2002) The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 32:1–6

    Article  PubMed  CAS  Google Scholar 

  10. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441–450

    Article  PubMed  CAS  Google Scholar 

  11. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG (2003) Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 198:305–313

    Article  PubMed  CAS  Google Scholar 

  12. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS (1995) Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 10:149–157

    PubMed  CAS  Google Scholar 

  13. Dong J, McPherson CM, Stambrook PJ (2002) Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther 1:486–489

    PubMed  Google Scholar 

  14. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184:1953–1962

    Article  PubMed  CAS  Google Scholar 

  15. Antonysamy MA, Thomson AW (2000) Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 12:87–100

    Article  PubMed  CAS  Google Scholar 

  16. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625–631

    Article  PubMed  CAS  Google Scholar 

  17. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD (1996) Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004–2012

    PubMed  CAS  Google Scholar 

  18. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161:2817–2824

    PubMed  CAS  Google Scholar 

  19. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 161:6164–6170

    PubMed  CAS  Google Scholar 

  20. Silver DF, Hempling RE, Piver MS, Repasky EA (2000) Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 77:377–382

    Article  PubMed  CAS  Google Scholar 

  21. Averbook BJ, Schuh JL, Papay R, Maliszewski C (2002) Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother 25:27–35

    Article  PubMed  CAS  Google Scholar 

  22. Furumoto K, Soares L, Engleman EG, Merad M (2004) Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113:774–783

    Article  PubMed  CAS  Google Scholar 

  23. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58:380–383

    PubMed  CAS  Google Scholar 

  24. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K (1997) Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511–3516

    PubMed  CAS  Google Scholar 

  25. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, Guha C (1999) Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 59:6028–6032

    PubMed  CAS  Google Scholar 

  26. Silver DF, Hempling RE, Piver MS, Repasky EA (2000) Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 77:377–382

    Article  PubMed  CAS  Google Scholar 

  27. Ciavarra RP, Somers KD, Brown RR, Glass WF, Consolvo PJ, Wright GL, Schellhammer PF (2000) Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res 60:2081–2084

    PubMed  CAS  Google Scholar 

  28. Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD (2004) Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother 27:13–26

    Article  PubMed  CAS  Google Scholar 

  29. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD (2003) Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 52:535–545

    Article  PubMed  CAS  Google Scholar 

  30. Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL Jr, Schellhammer PF, Qian J, Ciavarra RP (2003) Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer 107:773–780

    Article  PubMed  CAS  Google Scholar 

  31. Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F, Bonnotte B (2000) Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 86:827–834

    Article  PubMed  CAS  Google Scholar 

  32. Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W, Lynch DH (1999) Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol 163:1289–1297

    PubMed  CAS  Google Scholar 

  33. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K (1997) Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511–3516

    PubMed  CAS  Google Scholar 

  34. Miller G, Pillarisetty VG, Shah AB, Lahrs S, DeMatteo RP (2003) Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol 170:3554–3564

    PubMed  CAS  Google Scholar 

  35. Yanagi K, Nagayama Y, Nakao K, Saeki A, Matsumoto K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K (2003) Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo. Int J Oncol 22:345–351

    PubMed  CAS  Google Scholar 

  36. Dong J, Bohinski RJ, Li YQ, Van Waes C, Hendler F, Gleich L, Stambrook PJ (2003) Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer. Cancer Gene Ther 10:96–104

    Article  PubMed  CAS  Google Scholar 

  37. Braun SE, Chen K, Blazar BR, Orchard PJ, Sledge G, Robertson MJ, Broxmeyer HE, Cornetta K (1999) Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther 10:2141–2151

    Article  PubMed  CAS  Google Scholar 

  38. Yang Q, Yang G, Wei L, Jia F, Wu M, Guo Y (2002) Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer. Zhonghua Yi Xue Za Zhi 82:775–779

    PubMed  CAS  Google Scholar 

  39. Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5:7–10

    Article  PubMed  CAS  Google Scholar 

  40. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238

    Article  PubMed  CAS  Google Scholar 

  41. Frohman MA, Dush MK, Martin GR (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A 85:8998–9002

    Article  PubMed  CAS  Google Scholar 

  42. Pettengill OS, Faris RA, Bell RH Jr, Kuhlmann ET, Longnecker DS (1993) Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am J Pathol 143:292–303

    PubMed  CAS  Google Scholar 

  43. Ryschich E, Werner J, Gebhard MM, Klar E, Schmidt J (2003) Angiogenesis inhibition with TNP-470, 2-methoxyestradiol and paclitaxel in experimental pancreatic carcinoma. Pancreas 26:166–172

    Article  PubMed  CAS  Google Scholar 

  44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265

    PubMed  CAS  Google Scholar 

  45. Alsheikhly AR, Zweiri J, Walmesley AJ, Watson AJ, Christmas SE (2004) Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following “suicide” gene therapy in a murine colon carcinoma model. Cancer Immunol Immunother 53:946–954

    Article  PubMed  CAS  Google Scholar 

  46. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, Atkinson EN, Bekele BN, Stephens LC, Minna JD, Roth JA, Ramesh R (2004) Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11:733–739

    Article  PubMed  CAS  Google Scholar 

  47. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M (1997) Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 57:2681–2686

    PubMed  CAS  Google Scholar 

  48. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3 Suppl):925s–932s

    PubMed  Google Scholar 

  49. Ryschich E, Noetzel T, Hinz U, Autschbach F, Ferguson D, Simon I, Weitz J, Froelich B, Klar E, Buchler MW, Schmidt J (2005) Control of T-cell mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 11:498–504

    PubMed  CAS  Google Scholar 

  50. de Visser KE, Kast WM (1999) Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13(8):1188–1199

    Article  PubMed  Google Scholar 

  51. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S (1994) The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180:1849–1860

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Ms. Claudia Bernardi and Ms. Irina Vöhringer for their excellent technical assistance.

Author information

Authors and Affiliations

  1. Dept. of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany

    E. Ryschich, G. Huszty, E. Schmidt, H. P. Knaebel, A. Märten, M. W. Büchler & J. Schmidt

  2. Dept. of Molecular Pathology, University of Heidelberg, Heidelberg, Germany

    N. Wentzensen

  3. Dept. of Gastroenterology, University of Heidelberg, Heidelberg, Germany

    J. Encke

Authors
  1. E. Ryschich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Huszty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Wentzensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. P. Knaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Encke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Märten
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. W. Büchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Schmidt.

Additional information

The first two authors contributed equally to the work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ryschich, E., Huszty, G., Wentzensen, N. et al. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer. Int J Colorectal Dis 22, 215–223 (2007). https://doi.org/10.1007/s00384-006-0118-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-006-0118-5

Keywords

Search

Navigation